Literature DB >> 10913332

Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.

E A O'Brien1, J H Williams, M J Marshall.   

Abstract

The stimulators of bone resorption, prostaglandin E(2) (PGE(2)) and 1,25-dihydroxyvitamin D(3) (1,25D(3)), act through osteoblast-like cells to activate osteoclasts. One candidate for the intermediary produced by osteoblasts that subsequently stimulates the osteoclast is osteoprotegerin ligand (OPGL). OPGL has been shown to stimulate osteoclast differentiation and activation. The aim of the work reported here was to determine if soluble recombinant extracellular domain of human OPGL would bring about the change in osteoclast adhesion from the periosteum of mouse calvaria to the adjacent bone surface that occurs with the above-mentioned stimulators of resorption. This change in adherence or translocation of osteoclasts onto the bone surface required the expression and functioning of the integrin subunit, beta 3. We show that this soluble OPGL, like PGE(2) and 1,25D(3), stimulated the release of osteoclasts from the periosteum and their adherence to the bone surface accompanied by an increase in staining for immunolocalized integrin subunit beta 3. Recombinant human osteoprotegerin (OPG), which binds strongly to OPGL, inhibited this translocation of osteoclasts that occurred with PGE(2) and 1,25D(3), leaving integrin beta-3-negative osteoclasts on the periosteum. PGE(2) and 1,25D(3) increased the expression of messenger RNA for OPGL compared with indomethacin-treated controls after 6 h exposure. Evidence is presented that the change in the adhesion of osteoclasts from the periosteum to the bone surface, resulting in osteoclast activation, is mediated by OPGL. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913332     DOI: 10.1006/bbrc.2000.3129

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.

Authors:  Rodica Anghel; Alexander Bachmann; Meral Bekşac; Thomas Brodowicz; Jindřich Finek; Radko Komadina; Krzysztof Krzemieniecki; Istvan Lang; Jozef Marencak; Roger von Moos; Martin Pecherstorfer; Tamara Rordorf; Damir Vrbanec; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2013-07-06       Impact factor: 1.704

2.  Effects of spinal cord injury on osteoblastogenesis, osteoclastogenesis and gene expression profiling in osteoblasts in young rats.

Authors:  S-D Jiang; L-S Jiang; L-Y Dai
Journal:  Osteoporos Int       Date:  2006-10-12       Impact factor: 4.507

3.  RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.

Authors:  J T Ney; T Fehm; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-05       Impact factor: 2.915

Review 4.  Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.

Authors:  Juncheng Wei; Zhilin Wang; Danil Makarov; Xin Li
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

Review 5.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

Review 6.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

Review 7.  The role of RANK-ligand inhibition in cancer: the story of denosumab.

Authors:  Daniel Castellano; Juan Manuel Sepulveda; Ignacio García-Escobar; Alfredo Rodriguez-Antolín; Anna Sundlöv; Hernán Cortes-Funes
Journal:  Oncologist       Date:  2011-02-01

8.  Denosumab: an investigational drug for the management of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Biologics       Date:  2008-12

9.  Implanted bisphosphonates in bone cement affect bone markers in rat serum.

Authors:  Tomasz Mazurkiewicz; Lukasz Matuszewski; Anna Matuszewska; Magdalena Jaszek
Journal:  Int Orthop       Date:  2013-02-13       Impact factor: 3.075

Review 10.  Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.

Authors:  Joelle El-Amm; Ashley Freeman; Nihar Patel; Jeanny B Aragon-Ching
Journal:  Prostate Cancer       Date:  2013-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.